[1]孙俊,薛娟,计春燕,等.胃萎方联合瑞巴派特治疗萎缩性胃炎伴肠上皮化生疗效研究[J].陕西中医,2026,(4):497-501.[doi:DOI:10.3969/j.issn.1000-7369.2026.04.012]
　SUN Jun,XUE Juan,JI Chunyan,et al.Efficacy study of Weiwei formula combined with Rebamipide in the treatment of atrophic gastritis with intestinal metaplasia[J].,2026,(4):497-501.[doi:DOI:10.3969/j.issn.1000-7369.2026.04.012]
点击复制

胃萎方联合瑞巴派特治疗萎缩性胃炎伴肠上皮化生疗效研究

《陕西中医》[ISSN:1000-7369/CN:61-1281/TN]

卷:
期数:
2026年4期
页码:
497-501
栏目:
临床研究
出版日期:
2026-04-05

文章信息/Info

Title:
Efficacy study of Weiwei formula combined with Rebamipide in the treatment of atrophic gastritis with intestinal metaplasia
作者:
孙俊; 薛娟; 计春燕; 黄景荣; 章诗伟; 吉洪亮; 胡潇
（湖北省中西医结合医院消化内科，湖北 武汉 430015)
Author(s):
SUN Jun; XUE Juan; JI Chunyan; HUANG Jingrong; ZHANG Shiwei; JI Hongliang; HU Xiao
(Department of Gastroenterology,Hubei Provincial Hospital of Integrated Chinese and Western Medicine,Wuhan 430015，China)
关键词:
萎缩性胃炎; 胃萎方; 瑞巴派特; 肠上皮化生; 胃蛋白酶原水平; Musashi-1
Keywords:
Atrophic gastritis; Weiwei formula; Rebamipide; Intestinal metaplasia; Pepsinogen level; Musashi-1
分类号:
R 573.3
DOI:
DOI:10.3969/j.issn.1000-7369.2026.04.012
文献标志码:
A
摘要:
目的：探究胃萎方联合瑞巴派特治疗萎缩性胃炎（AG）伴肠上皮化生（IM）的临床疗效。方法：纳入96例AG伴IM患者，随机分为观察组和对照组，每组48例。对照组给予瑞巴派特治疗，观察组给予胃萎方联合瑞巴派特治疗。比较两组疗效、治疗前后中医证候积分、胃功能\[胃蛋白酶原（PG-Ⅰ、PG-Ⅱ）、胃泌素-17（G-17）\]、炎症因子\[白细胞介素-23（IL-23）、肿瘤坏死因子-α（TNF-α）、白细胞介素-6（IL-6）、降钙素原（PCT）\]、氧化应激水平\[一氧化氮（NO）、超氧化物歧化酶（SOD）、丙二醛（MDA）\]和胃黏膜Musashi-1（MSI-1）、CDX2阳性表达率。结果：观察组疗效优于对照组（P＜0.05）。治疗后，两组患者中医证候积分、G-17、PG-Ⅱ、IL-23、TNF-α、IL-6、PCT、MDA、MSI-1、CDX2阳性表达率降低，PG-Ⅰ、PG、NO、SOD增加，观察组优于对照组（均P＜0.05）。结论：胃萎方联合瑞巴派特治疗AG伴IM可降低患者中医证候积分和炎症因子水平，改善胃功能和氧化应激反应，降低胃黏膜MSI-1表达，疗效较好。
Abstract:
Objective:To explore the clinical efficacy of Weiwei formula combined with Rebamipide in the treatment of atrophic gastritis (AG) with intestinal metaplasia (IM).Methods:96 patients with AG complicated with IM were stochastically grouped into an observed group and a control group.The control group was treated with Rebamipide,while the observed group was treated with Weiwei formula combined with Rebamipide.The efficacy,the TCM symptom scores,gastric function \[pepsinogen (PG-Ⅰ and PG-Ⅱ),gastrin-17 (G-17)\],inflammatory factors \[interleukin-23 (IL-23),tumor necrosis factor-α (TNF-α),interleukin-6 (IL-6),procalcitonin (PCT)\],oxidative stress levels \[nitric oxide (NO),superoxide dismutase (SOD),malondialdehyde (MDA)\],and Musashi-1 （MSI-1）,CDX2 positive expression rate before and after treatment were compared between the two groups.Results:The healing effect of the observed group was higher than that of the control group (P<0.05).After treatment,the TCM syndrome scores,G-17,PG-Ⅱ,IL-23,TNF-α,IL-6,PCT,MDA,and MSI-1,CDX2 positive expression rates decreased in both groups,while PG-Ⅰ,NO,and SOD increased,the observed group was superior to the control group (all P<0.05).Conclusion:The combination of Weiwei formula and Rebamipide in treating AG complicated with IM is beneficial for reducing Chinese medicine syndrome scores and inflammatory factors,improving gastric function and oxidative stress response,and reducing MSI-1 expression in gastric mucosa,with great healing effects.

参考文献/References:

[1]SHAH S C,PIAZUELO M B,KUIPERS E J,et al.AGA clinical practice update on the diagnosis and management of atrophic gastritis:Expert review[J].Gastroenterology,2021,161(4):1325-1332.
[2]汪得胜,龚伟,肖冰,等.胃炎评价系统及基于肠化的胃炎评价系统对慢性萎缩性胃炎癌变风险的预测价值[J].中华消化内镜杂志,2020,37(11):781-786.
[3]中华医学会消化病学分会,中华医学会消化病学分会消化系统肿瘤协作组.中国慢性胃炎诊治指南(2022年，上海)[J].中华消化杂志,2023,43(3):145-175.
[4]王思梦,康立英,戎会丽,等.近五年中医药治疗慢性萎缩性胃炎临床研究进展[J].河北中医药学报,2021,36(6):53-57.
[5]王文斌,蒋丰娟,乔根芳.雷贝拉唑联合瑞巴派特治疗活动性胃溃疡的疗效及其对炎性反应的影响[J].世界复合医学,2022,8(12):185-189.
[6]李枝锦,吴平财.微观辨证论治脾虚湿浊型慢性萎缩性胃炎临床疗效及对血清胃泌素、胃蛋白酶原的影响[J].时珍国医国药,2022,33(3):643-646.
[7]纪天舒,袁泉,王苏童,等.探讨慢性萎缩性胃炎伴肠上皮化生的用药规律信息学研究[J].中药药理与临床,2024,40(7):86-93.
[8]中国中西医结合学会消化系统疾病专业委员会.慢性萎缩性胃炎中西医结合诊疗共识意见(2017年)[J].中国中西医结合消化杂志,2018,26(2):121-131.
[9]中华医学会消化病学分会.中国慢性胃炎共识意见(2017年,上海)[J].中华消化杂志,2017,37(11):721-738.
[10]卞立群,王凤云,陈婷,等.《中药新药用于慢性胃炎的临床疗效评价技术指导原则》中萎缩性胃炎与癌前病变内容解读[J].中国中西医结合消化杂志,2023,31(5):323-326.
[11]孙俊,薛娟,计春燕,等.慢性萎缩性胃炎伴肠上皮化生患者胃黏膜组织MSI-1、FOXA2表达变化及其临床意义[J].山东医药,2024,64(25):48-51.
[12]中华中医药学会脾胃病分会,中华医学会消化病学分会消化肿瘤协作组,中华医学会消化内镜学分会早癌协作组,等.中国整合胃癌前病变临床管理指南[J].胃肠病学,2021,26(2):91-111.
[13]裴蓓,温子昂,杨琦,等.慢性萎缩性胃炎患者肠化或异型增生的影响因素分析及预测模型的建立[J].中国实验方剂学杂志,2022,28(12):148-154.
[14]刘志华,刘晓雨,李京璠,等.慢性萎缩性胃炎浊毒蕴胃证内涵思考及诊断量表建立：基于文献研究及临床调查[J].时珍国医国药,2024,35(9):2302-2306.
[15]陈昌,陈一斌.胃萎方治疗慢性萎缩性胃炎的疗效探讨[J].中医临床研究,2022,1(11):99-101.
[16]陈丽凤,吴耀南.胃萎方治疗胃癌前期病变的疗效及其干预相关癌基因表达的研究[J].中医药通报,2016,15(5):47-50.
[17]MORI H,SUZUKI H,MATSUZAKI J,et al.Development of plasma ghrelin level as a novel marker for gastric mucosal atrophy after Helicobacter pylori eradication[J].Ann Med,2022,54(1):170-180.
[18]杨涛,田丽,林丽芳,等.制萎汤加减方联合四联法治疗慢性萎缩性胃炎患者的临床疗效及对其中医证候评分、胃蛋白酶原和炎症因子的影响[J].世界中西医结合杂志,2024,19(9):1818-1821.
[19]武鑫华,荀思佳,吴文轩,等.黄连的化学成分及药理作用研究进展[J].中医药学报,2024,52(7):110-116.
[20]魏江霞,李越峰,杨秀娟,等.当归不同药用部位的本草考证、化学成分、药理作用研究概况[J].中华中医药学刊,2024,42(10):127-134.
[21]YOUCHENG H E,XIAOLING Y,SIHAN L I,et al.Therapeutic effect of Qinghuayin against chronic atrophic gastritis through the inhibition of toll or interleukin-1 receptor domain-containing adaptor inducing interferon-beta signaling pathway[J].J Tradit Chin Med,2022,42(2):221-226.
[22]叶淑云,沈建冲,应旭卿.益气滋阴清热汤加减治疗阴虚热结证Hp感染合并CAG疗效[J].辽宁中医杂志,2024,51(12):108-111.
[23]闫奇.Hp感染及血清PCT、G-17在参与介导老年慢性萎缩性胃炎病理过程中的作用[J].中国老年学杂志,2023,43(7):1578-1580.
[24]WALLACE J L.Nitric oxide in the gastrointestinal tract:Opportunities for drug development[J].Br J Pharmacol,2019,176(2):147-154.
[25]刘亚,徐文倩,郭敏.能量代谢重编程在慢性萎缩性胃炎“炎-癌”转化中作用机制的研究进展[J].现代肿瘤医学,2024,32(8):1567-1572.
[26]TSUKANOV V V,SMIRNOVA O V,KASPAROV E V,et al.Dynamics of oxidative stress in helicobacter pylori-positive patients with atrophic body gastritis and various stages of gastric cancer[J].Diagnostics (Basel),2022,12(5):1203.
[27]陈淑婉.清化益胃汤联合气交灸对慢性萎缩性胃炎患者的应用价值[J].实用中西医结合临床,2024,24(1):17-19,23.
[28]顾洁,储开枫.麦冬汤加减对胃阴不足型慢性萎缩性胃炎患者EGF、CDX2表达的影响研究[J].现代消化及介入诊疗,2021,26(11):1404-1408.

相似文献/References:

[1]刘 睿,张 薇,杨 杰,等.降逆胃舒汤治疗萎缩性胃炎疗效及对患者病理评分的影响*[J].陕西中医,2020,(11):1539.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.006]
　LIU Rui,ZHANG Wei,YANG Jie,et al.Effect of Jiangni Weishu decoction on the pathological score of atrophic gastritis caused by helicobacter pylori infection[J].,2020,(4):1539.[doi:DOI:10.3969/j.issn.1000-7369.2020.11.006]

备注/Memo

备注/Memo:
湖北省中医药管理局资助项目（ZY2025Q017）；湖北省鄂州市科技计划项目（基础研究与人才创新专项）（EZ01-007-20230067）；湖北省中西医结合医院“杏林人才工程”院级科研重点项目（H2023Z005）
更新日期/Last Update: 2026-04-05